188 related articles for article (PubMed ID: 11125296)
1. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma.
Barillé S; Bataille R; Amiot M
Eur Cytokine Netw; 2000 Dec; 11(4):546-51. PubMed ID: 11125296
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
3. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells.
Barillé S; Collette M; Thabard W; Bleunven C; Bataille R; Amiot M
Cytokine; 2000 Sep; 12(9):1426-9. PubMed ID: 10976008
[TBL] [Abstract][Full Text] [Related]
4. Hepcidin and multiple myeloma related anemia.
Cucuianu A; Patiu M; Rusu A
Med Hypotheses; 2006; 66(2):352-4. PubMed ID: 16226391
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
Jourdan M; De Vos J; Mechti N; Klein B
Cell Death Differ; 2000 Dec; 7(12):1244-52. PubMed ID: 11175262
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
Lasfar A; Wietzerbin J; Billard C
Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
[TBL] [Abstract][Full Text] [Related]
7. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
8. Signalling and survival pathways in multiple myeloma.
Bommert K; Bargou RC; Stühmer T
Eur J Cancer; 2006 Jul; 42(11):1574-80. PubMed ID: 16797970
[TBL] [Abstract][Full Text] [Related]
9. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
Gadó K; Domján G; Hegyesi H; Falus A
Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias.
Treon SP; Anderson KC
Curr Opin Hematol; 1998 Jan; 5(1):42-8. PubMed ID: 9515202
[TBL] [Abstract][Full Text] [Related]
11. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
Nowell MA; Richards PJ; Fielding CA; Ognjanovic S; Topley N; Williams AS; Bryant-Greenwood G; Jones SA
Arthritis Rheum; 2006 Jul; 54(7):2084-95. PubMed ID: 16802343
[TBL] [Abstract][Full Text] [Related]
12. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias.
Hirano T
Int J Cell Cloning; 1991 May; 9(3):166-84. PubMed ID: 2061619
[TBL] [Abstract][Full Text] [Related]
14. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.
Thabard W; Barillé S; Collette M; Harousseau JL; Rapp MJ; Bataille R; Amiot M
Clin Cancer Res; 1999 Oct; 5(10):2693-7. PubMed ID: 10537331
[TBL] [Abstract][Full Text] [Related]
15. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 trans-signaling in inflammatory bowel disease.
Mitsuyama K; Sata M; Rose-John S
Cytokine Growth Factor Rev; 2006 Dec; 17(6):451-61. PubMed ID: 17045835
[TBL] [Abstract][Full Text] [Related]
17. Directly linked soluble IL-6 receptor-IL-6 fusion protein induces astrocyte differentiation from neuroepithelial cells via activation of STAT3.
Takizawa T; Yanagisawa M; Ochiai W; Yasukawa K; Ishiguro T; Nakashima K; Taga T
Cytokine; 2001 Mar; 13(5):272-9. PubMed ID: 11243705
[TBL] [Abstract][Full Text] [Related]
18. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration.
Aldeguer X; Debonera F; Shaked A; Krasinkas AM; Gelman AE; Que X; Zamir GA; Hiroyasu S; Kovalovich KK; Taub R; Olthoff KM
Hepatology; 2002 Jan; 35(1):40-8. PubMed ID: 11786958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
